{"id":"yellow-fever","safety":{"commonSideEffects":[{"rate":"10–30","effect":"Headache"},{"rate":"10–30","effect":"Myalgia"},{"rate":"5–15","effect":"Fever"},{"rate":"5–15","effect":"Injection site reaction (pain, erythema, swelling)"},{"rate":"5–10","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2108816","moleculeType":"Vaccine component"},"_dailymed":{"setId":"613aaac9-ec18-4b22-addb-599e1193e6f5","title":"YF-VAX (YELLOW FEVER VIRUS STRAIN 17D-204 LIVE ANTIGEN) INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION DILUENT (SODIUM CHLORIDE) INJECTION [SANOFI VACCINES US INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains a weakened (attenuated) form of the yellow fever virus that replicates in the body without causing disease, triggering both humoral (antibody) and cell-mediated immune responses. This primes the immune system to recognize and rapidly neutralize the wild-type yellow fever virus upon natural exposure, providing long-term protective immunity.","oneSentence":"The yellow fever vaccine stimulates the immune system to produce antibodies and cellular immunity against the yellow fever virus through a live attenuated viral strain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:58:27.218Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of yellow fever in endemic regions and travelers to yellow fever-endemic areas"}]},"trialDetails":[{"nctId":"NCT07103148","phase":"PHASE3","title":"A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-07-11","conditions":"Yellow Fever Immunization","enrollment":2440},{"nctId":"NCT02743455","phase":"PHASE1","title":"A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-07-05","conditions":"Yellow Fever, Yellow Fever Immunisation","enrollment":92},{"nctId":"NCT07222059","phase":"PHASE3","title":"Phase 3 Single Arm, Open Study on vYF in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2025-10-23","conditions":"Yellow Fever","enrollment":254},{"nctId":"NCT07002060","phase":"PHASE3","title":"Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults","status":"COMPLETED","sponsor":"Sanofi","startDate":"2025-05-22","conditions":"Yellow Fever Immunization","enrollment":640},{"nctId":"NCT06399003","phase":"PHASE3","title":"Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2024-06-28","conditions":"Measles-Mumps-Rubella","enrollment":1200},{"nctId":"NCT06694766","phase":"NA","title":"VAC-SIP-YF (Vaccination- Safety & Immunogenicity During Pregnancy- Yellow Fever)","status":"RECRUITING","sponsor":"Institut Pasteur","startDate":"2025-03-24","conditions":"Yellow Fever Vaccine","enrollment":270},{"nctId":"NCT06148025","phase":"PHASE4","title":"Antibiotics and Vaccine Immune Responses Study","status":"RECRUITING","sponsor":"South Australian Health and Medical Research Institute","startDate":"2023-11-23","conditions":"Vaccine Response Impaired","enrollment":348},{"nctId":"NCT04269265","phase":"PHASE1, PHASE2","title":"The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2020-07-01","conditions":"Yellow Fever","enrollment":43},{"nctId":"NCT00694655","phase":"PHASE4","title":"Human Immune Responses to Yellow Fever Vaccination","status":"COMPLETED","sponsor":"Emory University","startDate":"2008-05","conditions":"Yellow Fever","enrollment":239},{"nctId":"NCT04142086","phase":"PHASE1","title":"Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-01-15","conditions":"Yellow Fever (Healthy Volunteers)","enrollment":73},{"nctId":"NCT05172544","phase":"PHASE1","title":"Trial of an Inactivated Yellow Fever Virus Vaccine","status":"COMPLETED","sponsor":"Najit Technologies, Inc.","startDate":"2022-01-13","conditions":"Yellow Fever","enrollment":26},{"nctId":"NCT05155579","phase":"PHASE1","title":"Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2022-05-14","conditions":"Malaria","enrollment":593},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT05859490","phase":"PHASE1, PHASE2","title":"Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D Vaccination","status":"RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2023-08-01","conditions":"Yellow Fever, Immunization; Infection","enrollment":35},{"nctId":"NCT05801978","phase":"PHASE4","title":"Durability of Vaccine Responses","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-04-11","conditions":"Vaccine Response","enrollment":66},{"nctId":"NCT06718127","phase":"NA","title":"Description of the Immune Response to Yellow Fever Vaccination","status":"RECRUITING","sponsor":"Institut Pasteur","startDate":"2024-09-30","conditions":"Immunization, Infections","enrollment":38},{"nctId":"NCT04942210","phase":"PHASE2","title":"Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-07-01","conditions":"Yellow Fever, Healthy Volunteers","enrollment":568},{"nctId":"NCT06998004","phase":"PHASE1","title":"A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy Adults","status":"RECRUITING","sponsor":"AstriVax Therapeutics","startDate":"2024-06-16","conditions":"Yellow Fever, Rabies","enrollment":144},{"nctId":"NCT05011123","phase":"PHASE2","title":"Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-10-07","conditions":"Yellow Fever","enrollment":690},{"nctId":"NCT05421611","phase":"PHASE3","title":"A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2023-05-11","conditions":"Yellow Fever","enrollment":1824},{"nctId":"NCT01290055","phase":"PHASE4","title":"Turnover of Antigen Specific Lymphocytes and Monocytes After Immunization With the 17D Yellow Fever Vaccine","status":"COMPLETED","sponsor":"Sri Edupuganti","startDate":"2019-04-15","conditions":"Yellow Fever","enrollment":27},{"nctId":"NCT03725618","phase":"PHASE4","title":"Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2018-11-01","conditions":"Yellow Fever","enrollment":1788},{"nctId":"NCT04083430","phase":"PHASE4","title":"Cytotoxicity of Yellow Fever Specific CD8 T Cells Following YF-17D Vaccination","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Aarhus","startDate":"2019-10-08","conditions":"Healthy, Cytotoxicity, Yellow Fever Vaccination Reaction","enrollment":60},{"nctId":"NCT06815835","phase":"PHASE3","title":"Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-04-01","conditions":"Measles, Rubella, Yellow Fever","enrollment":1530},{"nctId":"NCT03920111","phase":"NA","title":"Flavivirus Cross-priming Potential of IMOJEV","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2021-04-16","conditions":"Japanese Encephalitis","enrollment":19},{"nctId":"NCT05443165","phase":"NA","title":"The Effect of Decision Support System on Symptom Self-Management in Non-Hodgkin Lymphoma Patients","status":"COMPLETED","sponsor":"Akdeniz University","startDate":"2024-01-31","conditions":"Decision Support System, Non-Hodgkin Lymphoma","enrollment":56},{"nctId":"NCT03591003","phase":"","title":"\"Persistence of Neutralizing Antibodies Against Yellow Fever (YF) in HIV-infected Patients\"","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Saint Pierre","startDate":"2015-06","conditions":"HIV Infections, Yellow Fever Vaccine","enrollment":200},{"nctId":"NCT05644145","phase":"NA","title":"Immunogenicity of Yellow Fever Vaccine in a Pediatric Population Vaccinated at 12-23 Months of Age in Argentina","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ministry of Public Health, Argentina","startDate":"2022-12-06","conditions":"Yellow Fever","enrollment":361},{"nctId":"NCT01244802","phase":"","title":"Characterization of Human Memory Immune Responses to Prior Yellow Fever Vaccination","status":"ENROLLING_BY_INVITATION","sponsor":"Emory University","startDate":"2010-11","conditions":"Yellow Fever Vaccine","enrollment":300},{"nctId":"NCT05450770","phase":"NA","title":"Immunity to Yellow Fever in HIV-infected Patients 10 Years After a Primary Anti-yellow Fever Vaccination","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2024-11-01","conditions":"HIV Infections, Yellow Fever","enrollment":60},{"nctId":"NCT02963909","phase":"PHASE1","title":"A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-11-01","conditions":"Zika Virus Infection","enrollment":75},{"nctId":"NCT04059471","phase":"PHASE4","title":"Non- Inferiority Fractional-doses Trial for Yellow Fever Vaccine","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-11-11","conditions":"Yellow Fever","enrollment":900},{"nctId":"NCT06213506","phase":"PHASE2","title":"A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-01-15","conditions":"Salmonella Infections","enrollment":516},{"nctId":"NCT05447377","phase":"PHASE3","title":"A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants","status":"UNKNOWN","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2022-09-16","conditions":"Yellow Fever","enrollment":2216},{"nctId":"NCT05374317","phase":"PHASE4","title":"Study of the Safety and Immunogenicity of Reduced Doses of the US Yellow Fever Vaccine","status":"COMPLETED","sponsor":"US Army Medical Research Institute of Infectious Diseases","startDate":"2021-06-07","conditions":"Yellow Fever Vaccination Reaction","enrollment":88},{"nctId":"NCT05292508","phase":"NA","title":"Comparison of Rates of Antimicrobial Use in Febrile Patients With or Without the Use of C-reactive Protein Blood Test","status":"UNKNOWN","sponsor":"Patan Academy of Health Sciences","startDate":"2023-02-26","conditions":"Acute Febrile Illness, Use of Antimicrobial Agents, C-reactive Protein Level","enrollment":924},{"nctId":"NCT03938597","phase":"","title":"Investigation of Serious Adverse Events Following Vaccination Against Yellow Fever: Emphasis on Genetic Basis and Biological Markers","status":"UNKNOWN","sponsor":"The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)","startDate":"2017-01-30","conditions":"Drug-Related Side Effects and Adverse Reactions","enrollment":10},{"nctId":"NCT02555072","phase":"PHASE4","title":"Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)","startDate":"2016-07","conditions":"Yellow Fever Vaccine, Immunity","enrollment":4761},{"nctId":"NCT05901454","phase":"NA","title":"Yellow Fever Human Infection Model With YF-17D","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2023-02-17","conditions":"Yellow Fever","enrollment":30},{"nctId":"NCT05568953","phase":"PHASE2","title":"An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity","status":"UNKNOWN","sponsor":"Singapore General Hospital","startDate":"2022-09-28","conditions":"Infectious Disease, Yellow Fever, Japanese Encephalitis","enrollment":70},{"nctId":"NCT03180359","phase":"NA","title":"Vaccines Immunogenicity in Renal, Hepatic, Cardiac or Pulmonary Transplanted Children","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2016-01-01","conditions":"Transplantation","enrollment":55},{"nctId":"NCT05332197","phase":"PHASE3","title":"Booster Vaccine for Yellow Fever","status":"UNKNOWN","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2022-05-16","conditions":"Yellow Fever","enrollment":750},{"nctId":"NCT00788151","phase":"PHASE2","title":"Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-09-26","conditions":"Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":300},{"nctId":"NCT01436396","phase":"PHASE3","title":"Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-09-07","conditions":"Dengue, Dengue Hemorrhagic Fever, Yellow Fever","enrollment":792},{"nctId":"NCT01488890","phase":"PHASE2","title":"Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-12-06","conditions":"Dengue, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":390},{"nctId":"NCT02991495","phase":"PHASE4","title":"Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE)","status":"COMPLETED","sponsor":"Epicentre","startDate":"2017-11-06","conditions":"Yellow Fever","enrollment":1630},{"nctId":"NCT04387760","phase":"PHASE2","title":"Favipiravir vs Hydroxychloroquine vs Control in COVID -19","status":"COMPLETED","sponsor":"Royal College of Surgeons in Ireland - Medical University of Bahrain","startDate":"2020-08-11","conditions":"SARS-CoV 2, COVID-19","enrollment":150},{"nctId":"NCT02699099","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-05-10","conditions":"Malaria, Malaria Vaccines","enrollment":699},{"nctId":"NCT03891420","phase":"PHASE1","title":"A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19","status":"TERMINATED","sponsor":"BioCryst Pharmaceuticals","startDate":"2020-04-09","conditions":"COVID-19, Yellow Fever","enrollment":24},{"nctId":"NCT03342898","phase":"PHASE3","title":"Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-02-28","conditions":"Dengue","enrollment":900},{"nctId":"NCT04416477","phase":"","title":"Duration of Immunity 10 Years After a Dose-response Study With Yellow Fever Vaccine - Complementary Study","status":"UNKNOWN","sponsor":"The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)","startDate":"2019-04-08","conditions":"Yellow Fever Vaccine","enrollment":255},{"nctId":"NCT03116802","phase":"PHASE2","title":"Yellow Fever Vaccine on Statin/ Non Statin Subjects","status":"COMPLETED","sponsor":"Singapore General Hospital","startDate":"2017-03-08","conditions":"Yellow Fever Vaccine, Yellow Fever","enrollment":37},{"nctId":"NCT03458780","phase":"","title":"Yellow Fever Immune Response at Single Cell Resolution","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"2016-08-22","conditions":"Healthy","enrollment":6},{"nctId":"NCT03776786","phase":"PHASE1","title":"Safety and Tolerability of an Antibody Against Yellow Fever Virus (TY014) in Humans","status":"COMPLETED","sponsor":"Tysana Pte Ltd","startDate":"2018-12-06","conditions":"Treatment of Acute Yellow Fever Virus Infection","enrollment":37},{"nctId":"NCT01345240","phase":"PHASE3","title":"Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-17","conditions":"Malaria, Malaria Vaccines","enrollment":705},{"nctId":"NCT03907449","phase":"","title":"Preview Rapid Strep A Test Method Comparison Study","status":"SUSPENDED","sponsor":"Guangzhou Wondfo Biotech Co., Ltd","startDate":"2019-03-19","conditions":"Strep Throat","enrollment":320},{"nctId":"NCT01391819","phase":"NA","title":"Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-09-06","conditions":"Dengue","enrollment":2117},{"nctId":"NCT03368495","phase":"PHASE4","title":"Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines","status":"COMPLETED","sponsor":"Alba Maria Ropero","startDate":"2015-11-23","conditions":"Vaccine Response Impaired","enrollment":851},{"nctId":"NCT03430388","phase":"NA","title":"Yellow Fever Vaccine in Patients With Rheumatic Diseases","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2018-01-31","conditions":"Systemic Lupus, Rheumatoid Arthritis, Spondyloarthritis","enrollment":600},{"nctId":"NCT03541694","phase":"","title":"Passive Enhanced Safety Surveillance of Stamaril® Vaccine in Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-11","conditions":"Yellow Fever","enrollment":622},{"nctId":"NCT02710045","phase":"NA","title":"The Interaction Between Measles and DTP Vaccination","status":"COMPLETED","sponsor":"Medical Research Council Unit, The Gambia","startDate":"2007-11","conditions":"Non-target Heterologous Effects of Vaccines, Vaccine Interactions","enrollment":302},{"nctId":"NCT01426243","phase":"PHASE3","title":"The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient.","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2011-07","conditions":"HIV Infection, Yellow Fever","enrollment":71},{"nctId":"NCT02286895","phase":"PHASE4","title":"Immune Response to Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali","status":"COMPLETED","sponsor":"PATH","startDate":"2014-10","conditions":"Diarrhea Rotavirus","enrollment":600},{"nctId":"NCT00436007","phase":"PHASE2","title":"Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-30","conditions":"Malaria","enrollment":511},{"nctId":"NCT03132311","phase":"PHASE4","title":"Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals","status":"RECRUITING","sponsor":"Oswaldo Cruz Foundation","startDate":"2017-05-29","conditions":"HIV Infections","enrollment":400},{"nctId":"NCT01847872","phase":"PHASE4","title":"IPV Clinical Trial - The Gambia","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2013-07","conditions":"Poliomyelitis","enrollment":1504},{"nctId":"NCT00730288","phase":"PHASE2","title":"Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-08","conditions":"Dengue, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":35},{"nctId":"NCT03338231","phase":"","title":"Clinical Study of Immunity Duration of Yellow Fever Vaccine in Military","status":"COMPLETED","sponsor":"The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)","startDate":"2017-03-27","conditions":"Yellow Fever Vaccine","enrollment":374},{"nctId":"NCT02990182","phase":"","title":"Complementary Study of the Duration of Post-vaccination Against Yellow Fever Immunity in Children","status":"UNKNOWN","sponsor":"Oswaldo Cruz Foundation","startDate":"2015-04","conditions":"Yellow Fever","enrollment":60},{"nctId":"NCT00995865","phase":"PHASE1","title":"Trial of Yellow Fever Inactivated Vaccine","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2010-01","conditions":"Yellow Fever","enrollment":60},{"nctId":"NCT01943305","phase":"PHASE2","title":"The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans","status":"COMPLETED","sponsor":"Singapore General Hospital","startDate":"2013-10","conditions":"Yellow Fever, Encephalitis, Japanese","enrollment":84},{"nctId":"NCT02572518","phase":"","title":"Immunity After Two Doses of Yellow Fever Vaccine","status":"COMPLETED","sponsor":"The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)","startDate":"2014-05","conditions":"Yellow Fever","enrollment":440},{"nctId":"NCT02383680","phase":"","title":"Yellow Fever Vaccination Under Low Dose Methotrexate Therapy","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2014-12","conditions":"Rheumatic, Dermatologic Disorders","enrollment":30},{"nctId":"NCT01765413","phase":"NA","title":"Training Study to Characterize Biomarkers to Chickenpox and Yellow Fever Vaccines","status":"COMPLETED","sponsor":"University of Surrey","startDate":"2013-09","conditions":"Healthy","enrollment":48},{"nctId":"NCT01466387","phase":"PHASE3","title":"A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults","status":"COMPLETED","sponsor":"Novartis","startDate":"2011-11","conditions":"Meningococcal Disease, Meningococcal Meningitis, Typhoid","enrollment":552},{"nctId":"NCT00723489","phase":"PHASE1, PHASE2","title":"Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-08","conditions":"Atopic Dermatitis","enrollment":82},{"nctId":"NCT00254826","phase":"PHASE1","title":"Yellow Fever Virus Vaccine and Immune Globulin Study","status":"COMPLETED","sponsor":"Emory University","startDate":"2006-06","conditions":"Viremia","enrollment":80},{"nctId":"NCT00982137","phase":"PHASE2","title":"Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-07","conditions":"Japanese Encephalitis, Yellow Fever","enrollment":108},{"nctId":"NCT00708630","phase":"NA","title":"The Effect of Extended Yellow Fever Vaccine Information on Symptom Reports Following Vaccination","status":"COMPLETED","sponsor":"University of Auckland, New Zealand","startDate":"2008-06","conditions":"Vaccination","enrollment":100},{"nctId":"NCT01182532","phase":"NA","title":"A Clinical Trial to Evaluate the Effectiveness and Safety of Chinese Medicine in the Treatment of Mild Type of Hand, Foot, and Mouth Disease","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine","startDate":"2010-05","conditions":"Hand, Foot and Mouth Disease","enrollment":3000},{"nctId":"NCT00616356","phase":"","title":"Characterization of T Cell Responses Following Yellow Fever Virus Vaccination in Healthy Adults","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"2007-12","conditions":"Yellow Fever","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8454,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["YF VAX®"],"phase":"marketed","status":"active","brandName":"Yellow Fever","genericName":"Yellow Fever","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi-pasteur-a-sanofi-company","modality":"Biologic","firstApprovalDate":"","aiSummary":"The yellow fever vaccine stimulates the immune system to produce antibodies and cellular immunity against the yellow fever virus through a live attenuated viral strain. Used for Prevention of yellow fever in endemic regions and travelers to yellow fever-endemic areas.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}